Financial Data and Key Metrics Changes - For the six months ended December 31, 2021, the company recorded a net loss of approximately $7.3 million or $0.56 per share, compared to a net loss of $3.8 million or $0.68 per share for the same period in 2020, indicating an increase in net loss attributed to higher R&D spending [32][34] - R&D expenses for the six months were approximately $4 million, up from $1.8 million in the previous year, primarily due to increased activities related to the INM-755 clinical trial [32][33] - G&A expenses were approximately $3.2 million for the period, compared to $1.6 million for the same period last year, driven by personnel expenses, legal fees, and higher insurance fees [34] Business Line Data and Key Metrics Changes - The company realized B2B sales of bulk rare cannabinoids of approximately $300,000 for the three months ended December 31, 2021, marking the first quarter that revenues from the BayMedica acquisition were included [36] - Prior to the acquisition, BayMedica had cumulative revenues of $2.4 million over a 20-month period ending September 2021, primarily from one product, CBC [38] Market Data and Key Metrics Changes - The current market prices for rare cannabinoids range from approximately $17,000 to $30,000 per kilogram, with the company believing it can be competitive on pricing while maintaining attractive margins [15] - CBDV and THCV are expected to have high demand, with CBDV thought to have potential applications in conditions such as autism spectrum disorder, and THCV showing promise in appetite suppression and weight loss [66] Company Strategy and Development Direction - The company aims to position itself as a leader in the rare cannabinoid space, focusing on both pharmaceutical and health and wellness markets [9][10] - The acquisition of BayMedica is central to the company's strategy, allowing for expedited integration and commercial activities, including product launches [10][12] - The company plans to launch new products, enhance sales and marketing infrastructure, and develop new cannabinoid analogues for pharmaceutical applications [13][16] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by the COVID-19 pandemic, including global supply disruptions and staffing issues affecting development timelines [28] - The company expects to see considerable progress in advancing its programs over the next few months, with key priorities including product launches and updates on clinical trials [29] Other Important Information - The company announced the hiring of Jerry Griffin as Vice President of Sales and Marketing at BayMedica, aimed at accelerating commercial plans and growing market share [17] - The company filed a shelf prospectus for $50 million, which is a typical component of a capital market strategy for growth companies [40] Q&A Session Summary Question: When can we expect initial data from the INM-755 trial? - Management indicated there will be no interim analysis, and results will be announced after the trial is completed and data analyzed [46] Question: What would be considered positive data in the EB trial? - The trial design allows each patient to serve as their own control, comparing the active cream to a vehicle cream [47] Question: Can you provide insights on peak sales for the new cannabinoid products? - Management stated that it is difficult to forecast peak sales due to limited data on market opportunities for rare cannabinoids [50][52] Question: What level of revenues is needed for BayMedica to break even? - Management noted that it is challenging to determine breakeven levels due to various factors affecting capital deployment and product launches [56] Question: What is the expected cash runway for the company? - The company expects its cash and cash equivalents to be sufficient to fund operations into the first quarter of fiscal 2023 [42]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-39685 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-39685 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada ...

Financial Data and Key Metrics Changes - For the fiscal year ended June 30, 2021, the company recorded a net loss of approximately $10 million or $1.52 per share, compared to a net loss of approximately $9 million or $1.71 per share for the previous year [34] - Cash and cash equivalents at the end of the year were approximately $7.4 million, an increase from approximately $5.8 million at the end of the previous fiscal year [37] Business Line Data and Key Metrics Changes - Research and development expenses for the year were approximately $5.3 million, a slight decrease from approximately $5.8 million in the previous year [35] - General and administrative expenses increased to approximately $4.5 million for fiscal year 2021, compared to approximately $3.2 million for the previous year [36] Market Data and Key Metrics Changes - BayMedica's initial product, Prodiol CBC, has generated cumulative revenues exceeding $2.5 million since sales began in December 2019, with an average growth of 35% quarter-on-quarter for the year ended June 30, 2021 [15] Company Strategy and Development Direction - The company announced a transformative acquisition of BayMedica, which specializes in the manufacturing and commercialization of rare cannabinoids, positioning InMed as a leader in this sector [9][12] - The IntegraSyn program achieved a pivotal milestone with an improved yield of 5 grams per liter, significantly exceeding industry standards, which supports the advancement to large-scale production [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming catalysts, including the closing of the BayMedica acquisition and the commencement of Phase 2 clinical trials for INM-755 [28][30] - The company is monitoring the decline in share price closely, attributing it to the overall market performance of cannabis companies, and is allocating resources to enhance investor relations [30] Other Important Information - The company is preparing for the integration of BayMedica, which is expected to accelerate commercial activities and revenue growth [18] - The IntegraSyn system is designed to produce pharmaceutical-grade cannabinoids efficiently, with plans to scale up production [22] Q&A Session Summary Question: What should be expected for revenues in fiscal year 2022 regarding the BayMedica acquisition? - Management indicated it is too early to provide specific revenue guidance for 2022 as the acquisition has not yet closed, but they expect growth based on historical performance [41][42] Question: How will the IntegraSyn business model play out? - The business model will depend on the specific cannabinoid being produced and its intended use, with a focus on optimizing manufacturing processes for cost-effectiveness [43][44] Question: What is the expected timeline for data release after enrollment completion for INM-755? - The treatment period is 28 days, followed by a one-week safety follow-up, with data expected to be available several months after the last patient completes the trial [47][48] Question: What is the rollout plan for additional cannabinoids from BayMedica? - Management stated that it is too early to provide specific timing for additional cannabinoid rollouts, as they need to assess integration and prioritize product launches [50][51] Question: What types of customers are purchasing the CBC product? - Currently, sales are primarily B2B, with customers including wholesale distributors and smaller manufacturers of cannabinoid-based products [54][56] Question: What is the timing for an IND filing for INM-088? - The company anticipates filing an IND in the later half of the next calendar year, pending completion of necessary toxicology studies [57][58]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number: 001-39685 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 8 ...

InMed Pharmaceuticals Inc. (NASDAQ:INM) Q3 2021 Earnings Conference Call May 13, 2021 11:00 AM ET Company Participants Bruce Colwill - Chief Financial Officer Eric Adams - President and Chief Executive Officer Eric Hsu - Senior Vice President, Preclinical Research and Development Alexandra Mancini - Senior Vice President, Clinical and Regulatory Affairs Michael Woudenberg - Vice President, Chemistry, Manufacturing and Control Conference Call Participants Scott Henry - ROTH Capital Markets Operator Good morn ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Exact name of registrant as specified in its charter) British Columbia, Canada 98-1067994 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-39685 INMED PHARMACEUTICA ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 or Commission File Number: 001-39685 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 98-1067994 (State or other jurisdiction of incorporation or organization) Suite 310 - 815 W. Hastings Street, Vancouver, B.C. (Address of Principal ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the quarterly period ended September 30, 2020 or For the transition period from __________ to __________ Commission File Number: 001-39685 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 98-1067994 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Suite 310 - 815 W. Hastings Street, Vancouver, B.C. Canada V6C 1B4 (A ...

InMed Pharmaceuticals Inc. (IMLFF) Q4 2020 Earnings Conference Call September 8, 2020 11:30 AM ET Company Participants Brendan Payne - Director, Investor Relations Eric Adams - President & Chief Executive Officer Bruce Colwill - Chief Financial Officer Eric Hsu - Senior Vice President, Pre-Clinical Research & Development Alexandra Mancini - Senior Vice President, Clinical & Regulatory Affairs Conference Call Participants Maxim Jacobs - Edison Group Operator Good morning. My name is Veronica, and IÂ'll be yo ...